Hansoh Pharmaceutical Group Company Limited Stock

Equities

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. 16:08:09 19/06/2025 HKT 5-day change 1st Jan Change
27.75 HKD -1.42% Intraday chart for Hansoh Pharmaceutical Group Company Limited -7.19% +60.59%

Valuation: Hansoh Pharmaceutical Group Company Limited

Capitalization 153B 167B 21.32B 18.51B 17.42B 15.83B 29.18B 1,843B 32.7B 205B 79.04B 843B 80.01B 78.31B 3,083B P/E ratio 2025 *
32.8x
P/E ratio 2026 * 31.3x
Enterprise value 128B 139B 17.77B 15.43B 14.52B 13.19B 24.31B 1,536B 27.25B 170B 65.87B 702B 66.68B 65.26B 2,569B EV / Sales 2025 *
9.36x
EV / Sales 2026 * 8.35x
Free-Float
18.75%
Yield 2025 *
1.02%
Yield 2026 * 1.05%
More valuation ratios * Estimated data
Dynamic Chart
Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing 06-05 CI
Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing 06-04 RE
Hansoh Pharma's Lung Cancer Drug Aumseqa Wins UK Marketing Approval 06-04 MT
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$25.64 From HK$19.86, Keeps at Neutral 06-03 MT
Hansoh Pharma Licenses GLP-1 Drug to Nasdaq-listed Regeneron in $2 Billion Deal 06-03 MT
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle 06-03 RE
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals 06-02 RE
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug 06-02 DJ
Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products Administration 05-31 CI
Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA 05-31 RE
Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug 05-30 MT
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration 05-30 CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration 05-30 CI
More news
1 day-1.42%
1 week-7.19%
Current month+7.35%
1 month+18.09%
3 months+31.83%
6 months+51.31%
Current year+60.59%
More quotes
1 week 26.8
Extreme 26.8
30.85
1 month 23.85
Extreme 23.85
30.85
Current year 15.96
Extreme 15.96
30.85
1 year 15.32
Extreme 15.32
30.85
3 years 9.41
Extreme 9.41
30.85
5 years 9.41
Extreme 9.41
46.7
10 years 9.41
Extreme 9.41
46.7
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 02/12/2015
Corporate Secretary 36 24/01/2025
Corporate Secretary 57 01/08/2018
Director TitleAgeSince
Chairman 64 02/12/2015
Director/Board Member 48 11/03/2016
Director/Board Member 38 02/12/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.42%-7.19%+60.22%+107.09% 21.32B
-0.78%-2.92%-11.94%+169.86% 705B
-1.08%-2.92%+3.49%-11.05% 363B
+0.60%-7.01%-50.94%+26.84% 331B
+0.01%-3.14%+8.25%+34.14% 328B
-0.37%-5.58%+3.04%-15.47% 254B
-0.19%-3.32%+0.95%+19.05% 228B
-0.23%-4.67%-14.79%+4.59% 220B
+1.29%-1.28%-38.05%-6.30% 199B
-0.19%-0.79%-5.39%+23.34% 156B
Average -0.05%-2.99%-4.52%+35.21% 280.47B
Weighted average by Cap. +0.06%-3.00%-10.95%+50.58%
See all sector performances

Financials

2025 *2026 *
Net sales 13.65B 14.91B 1.9B 1.65B 1.55B 1.41B 2.6B 164B 2.91B 18.22B 7.04B 75.07B 7.13B 6.97B 275B 14.82B 16.19B 2.06B 1.79B 1.68B 1.53B 2.82B 178B 3.16B 19.78B 7.64B 81.52B 7.74B 7.57B 298B
Net income 4.61B 5.03B 641M 556M 523M 476M 877M 55.37B 983M 6.15B 2.38B 25.33B 2.4B 2.35B 92.65B 4.86B 5.3B 676M 586M 552M 501M 924M 58.38B 1.04B 6.48B 2.5B 26.7B 2.53B 2.48B 97.68B
Net Debt -25.54B -27.89B -3.55B -3.08B -2.9B -2.64B -4.86B -307B -5.45B -34.08B -13.17B -140B -13.33B -13.05B -514B -29.47B -32.19B -4.1B -3.56B -3.35B -3.04B -5.61B -354B -6.29B -39.33B -15.2B -162B -15.39B -15.06B -593B
More financial data * Estimated data
Logo Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
Employees
8,989
More about the company
Date Price Change Volume
19/06/25 27.75 $ -1.42% 18,519,015
18/06/25 28.15 $ -0.53% 7,875,888
17/06/25 28.30 $ -3.41% 13,084,480
16/06/25 29.30 $ -0.34% 16,406,100
13/06/25 29.40 $ -1.67% 16,290,100

Delayed Quote Hong Kong S.E., June 19, 2025 at 04:08 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
25.78CNY
Average target price
26.83CNY
Spread / Average Target
+4.08%
Consensus

Quarterly revenue - Rate of surprise